RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) In Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma

PURPOSE: To determine the safety of the mTOR inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients. METHODS AND MATERIALS: Everolimus was administered daily with concurrent radiation (60 Gy in 30 fractions) and temozolomi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chinnaiyan, Prakash, Won, Minhee, Wen, Patrick Y., Rojiani, Amyn M., Wendland, Merideth, Dipetrillo, Thomas A., Corn, Benjamin W., Mehta, Minesh P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766839/
https://ncbi.nlm.nih.gov/pubmed/23725999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2013.04.036
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares